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Introduction: The Accreditation Collaborative for the
Conduct of Research, Evaluation and Designated
Investigations through Teamwork—Cost–Benefit
Analysis (ACCREDIT-CBA (Acute)) study is designed to
determine and make explicit the costs and benefits of
Australian acute care accreditation and to determine the
effectiveness of acute care accreditation in improving
patient safety and quality of care. The cost–benefit
analysis framework will be provided in the form of an
interactive model for industry partners, health
regulators and policy makers, accreditation agencies
and acute care service providers.
Methods and design: The study will use a mixed-
method approach to identify, quantify and monetise the
costs and benefits of accreditation. Surveys, expert
panels, focus groups, interviews and primary and
secondary data analysis will be used in cross-sectional
and case study designs.
Ethics and dissemination: The University of New
South Wales Human Research Ethics Committee has
approved this project (approval number HREC 10274).
The results of the study will be reported via
peer-reviewed publications, conferences and
seminar resentations and will form part of a doctoral
thesis.
INTRODUCTION
Despite its widespread implementation, the
costs and benefits of acute health services
accreditation have not been clearly defined,
identified and quantified.1–5 An economic
framework is needed to systematically assess
and compare these costs and benefits. This
study protocol applies economic evaluation
techniques using a purpose-designed frame-
work to answer our research question as to
whether acute care accreditation in Australia




▪ This study uses economic evaluation techniques to
assess the costs and benefits of acute care
accreditation in Australian health services. The
objective is to provide an interactive model of the
costs and benefits from the perspective of a broad
range of stakeholders. The model can also be used
to assess the effectiveness of accreditation in
improving patient safety and quality of care.
Key messages
▪ Despite its widespread implementation, the costs
and benefits of acute care accreditation have not
been clearly defined, identified and quantified.
▪ Economic evaluation techniques such as costs–
benefit analysis can help determine whether
accreditation is an effective driver of patient
safety and quality of care.
▪ This protocol provides a unique, specifically
designed framework and a number of purpose
built tools to systematically assess the costs and
benefits of acute care accreditation.
Strengths and limitations of this study
▪ The strength of this study lies in using economic
evaluation techniques to establish the role of
acute care accreditation as an effective audit tool;
this has not been accomplished previously.
▪ One limitation in determining the impact of
accreditation in Australia is the lack of a suitable
control group given the widespread implementa-
tion of accreditation.
▪ In keeping with the tenets of an inclusive societal
framework,62 stakeholders from group (2A) will
be included in the list of identified stakeholders.
Those in group (2B) will be closely reviewed for
inclusion based on their knowledge and perspec-
tive. The group of identified stakeholders will be
used throughout the study and referenced when
considering the individual costs and benefits to
ensure that the broader social framework is
addressed.
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Accreditation of acute health services in Australia
The International Society for Quality in Health Care
(ISQua), the peak body for health services accreditation,
defines accreditation as ‘public recognition of the achieve-
ment of standards by an organisation demonstrated
through independent assessment in relation to set stan-
dards’.6 Accreditation has been widely implemented fol-
lowing the establishment of the Joint Commission on
Accreditation of Hospitals (now, the Joint Commission) in
the USA in 1951.7 8 In Australia, accreditation was first
adopted for acute care services in 1974,9 with the
Australian Council on Healthcare Standards (ACHS) as
the main accrediting agency. Over subsequent years,
ACHS developed the Evaluation and Quality Improvement
Program (EQuIP). This accreditation programme com-
prises two external surveys within a 4-year accreditation
cycle.10 Facilities are assessed by trained external surveyors
using standards developed by ACHS in consultation
with healthcare industry experts.10 As part of the wider
health system reforms implemented by the Australian
Commonwealth Government, recently approved legisla-
tion requires all hospitals and day procedure services in
Australia to be assessed by an accreditation provider
approved by the Australian Commission on Safety and
Quality in Health Care (ACSQHC) using newly developed
National Safety and Quality Health Service (NSQHS) stan-
dards.11 Australian acute care accreditation is the focus of
this study. We include acute and high-risk inpatient activity
in our definition of acute care facilities (ACFs) in this
protocol.
Economic evaluation of health interventions
Health costs are a significant proportion of gross domes-
tic product, averaging 9.6% in 2010 for Organisation for
Economic and Co-operation Development countries.12
This, combined with persistent evidence of harm during
health service delivery,13–16 has resulted in an increasing
international focus on accountability and safety in
healthcare.17 18 Economic evaluation addresses these
issues by using a systematic framework to identify and
compare the costs and benefits of a policy or interven-
tion to determine whether implementation is effective
in achieving stated aims and also to compare different
policy proposals and interventions.19–21 In cost–benefit
analysis (CBA), the costs and benefits are each
expressed in monetary terms. This contrasts with other
techniques such as cost-effectiveness analysis (CEA) or
cost-utility analysis (CUA), which are used in assessing
health technologies. In CEA and CUA, the common
outcome denominator is not monetised, but expressed
in terms of a common utility measure such as Quality
Adjusted Life Years.22–25 CBA is advocated where there is
a broader range of outcomes and is usually a require-
ment for submitting a regulatory impact statement for
Australian government approval.19 CBA seems justified
as the most appropriate model to use in an Australian
health services context as the NSQHS standards cover
both organisational and clinical outcomes, which are
best measured using a common monetary denominator.
Although CBA can be used as an allocative efficiency
tool for comparing different projects, the requirement
to make the costs and benefits explicit in the analysis
framework can help clarify the goals, costs and benefits,
providing input into the design of future accreditation
systems in healthcare.26
Modelling the costs and benefits of a complex inter-
vention, such as accreditation, in a complex system, such
as an ACF, is a significant undertaking.27 Given the lack
of precedent discussed above, we have developed a
unique framework and a number of purpose-built tools
specifically designed for evaluating acute care accredit-
ation. Our SIQNS framework is synthesised from several
sources,20 21 28 29 and comprises five discrete activities
(1) scope and objectives; (2) identify costs and benefits;
(3) quantify costs and benefits; (4) calculate net social
benefits and (5) sensitivity analysis (figure 1).
Scope and objectives
The aim of the study is to create an interactive model
that can be accessed by health service providers,
accreditation bodies, quality and safety agencies, govern-
ments and researchers to both test the assumptions in
the model and to determine the cost–benefit calcula-
tions of acute care accreditation at both the national
and local service levels.28 The lack of research in this
field, as well as the complexity of both the intervention
(accreditation) and system (acute healthcare), indicates
that an important objective will be to make explicit the
costs and benefits of accreditation.1 2 27 29 30
Establishment of the study parameters will be
informed by a review of the research literature and ana-
lysis of the characteristics of accredited ACFs. These
activities will also help determine the indicator selection
process to identify and quantify the benefits of accredit-
ation. A critical element is to identify the stakeholders
involved in the acute care accreditation process.
Although accreditation agencies and ACFs are the most
obvious groups affected, a broader societal framework is
required when assessing regulatory impact to ensure
that equity and impact are meaningfully accounted for
in the analysis.20
Our initial analysis has identified a key constraint, in
that ACFs do not account for accreditation activities as a
separate cost item.31 Our approach, outlined below, is to
accept that large-scale data gathering on costs would not
be possible within the scope of the study and will be a
challenge over time. Instead, we will use a smaller study
sample and have this validated by an expert panel.
Accreditation benefits, in terms of both clinical and
organisational outcomes, are more likely to be assessed
using secondary data, but are more difficult to identify
partly owing to a lack of clarity in terms of measurable
endpoints. In addition, a full impact analysis of all bene-
fits for all stakeholders will be outside the study scope. A
further constraint is that an economic appraisal would
ideally be conducted with a control group (either
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randomly assigned or with data collected for a before
and after comparison) in order to compare different
outcomes.32 This is not possible in Australia where acute
care accreditation is widely implemented (93% of public
hospital beds in 2010 and 84% of private hospital beds
in 2008–2009).33 However, we can analyse data before
and after introduction of new standards, review indicator
activity against accreditation scores and analyse changes
over time.
Identify costs and benefits
To identify the incremental costs of accreditation, we
need to determine costs that are only incurred due to
the accreditation process.34 We will first review the stake-
holders for potential costs and exclude transfer pay-
ments to avoid double counting. We will then assess
costs for a small number of ACFs (n=10) using our
purpose designed assessment tool based on questions
posed in similar cost surveys,35–38 and the Business Cost
Calculator which has been designed to help Australian
businesses compute business compliance costs.7 10 39 40
International accreditation agencies, for example, the
Joint Commission, ACHS and Accreditation Canada,
identify improvements in patient safety and quality of
care as the main benefits of health services accredit-
ation.7 10 40 Within an Australian context, we reviewed
the benefits outlined by ACSQHC in a recent regulatory
impact statement on the new NSQHS standards.41 In
addition, the Australian National Health Performance
Authority’s (NHPA’s) performance and accountability
framework has defined the indicators used to assess
effectiveness of care in ACFs. We will map our stake-
holder analysis with the ACSQHC benefits and the
NHPA adverse and sentinel event measures to identify
quality and safety indicators.
In our choice of indicators, we need to distinguish
whether a lack of change in the indicator is due to a
lack of compliance with the accreditation standard, or
whether compliance with the standard results in
change in an indicator. We have adapted the approach
used in measuring quality outcomes in US hospitals.42
This recommends that indicators must meet four
key accountability criteria: research—robust evidence;
accuracy—whether the process has been carried out
satisfactorily; proximity—a clear and direct link between
accreditation and the indicator; and, no adverse effects—
no unintended or unwanted actions. As accreditation is
usually just one facet of a quality and safety framework,
we have added a further criterion—specificity—to deter-
mine how easy it is to isolate the effects of accreditation
from other safety and quality measures. This is import-
ant when determining the effectiveness of accreditation
versus other safety and quality initiatives.43 We specify
the type of indicator, as process indicators are often a
preferred measure of quality over outcome indicators.
This is due to a more direct link between the indicator
and the process being measured (the issue of proximity
in Chassin’s accountability criteria),42 but this can also
lead to estimation problems as only a narrow range of
factors is considered. Outcome indicators have an
Figure 1 SIQNS framework.
Mumford V, Greenfield D, Hinchcliff R, et al. BMJ Open 2013;3:e002381. doi:10.1136/bmjopen-2012-002381 3
Accredit-CBA (Acute)
group.bmj.com on September 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
advantage in that the data are often collected routinely,
but may need to be adjusted for other factors such as
patient acuity and complexity.43–45 We will need to con-
sider whether the chosen indicators need to be weighted
to reflect both suitability (in terms of adherence to the
accountability criteria) and applicability (quality of data
collection and adjustment for patient mix). We will ask
an expert panel to review and validate our indicator
selections prior to quantifying the indicators for further
analysis.
Quantify costs and benefits
Once the costs have been identified for each ACF in our
sample, we will need to ensure that the results can be
scaled up and assessed on a national basis. Although
costs for initial accreditation can be higher than for
ongoing accreditation,38 46 we assume ongoing accredit-
ation costs for our sample, but include questions on esti-
mating the cost of implementing the new national
standards in the survey.
As the CBA model uses monetary values as the common
denominator, we will need to monetise the benefits identi-
fied. The techniques used will depend on the availability
of pricing and market data. For example, clinical outcome
indicators (such as hospital-acquired infection rates, or
complications resulting from inpatient falls) can be
matched to activity-based costing codes. These data can be
used to determine the potential cost savings from a reduc-
tion in infection or fall rates. Where we identify an indica-
tor but do not see a change in measurement, we will
include this in our sensitivity analysis, for example, the
costs associated with reducing hospital-acquired infections
by a stated amount. Where indicators can be identified
and quantified but lack pricing or market data, we will
monetise the effects using techniques such as revealed
and stated preference methods, where possible.21 26 47
Calculate net social benefit
Given that costs and benefits are likely to occur at differ-
ent times, we will need to adjust the timing differentials
using an appropriate discount rate. For CBA, both the
net social benefit (NSB) and the benefits–cost ratio
(BCR) are calculated. The NSB uses a net present value
method to derive an absolute measure of whether the
discounted (net) benefits are greater than the dis-
counted (net) costs when assessing proposals in a regu-
latory impact statement.19 22 The BCR is derived by
dividing the net benefits by the net costs to determine
an effective return on the costs and is used where the
absolute size of the investment is a determining factor,
for example, in a resource-constrained environment.
However, the BCR is subject to more variation depend-
ing on how the outcomes are treated.19 20 22
With questions on the table about whether accredit-
ation is more of an audit tool or quality improvement
tool,1 8 CBA can address both these issues by comparing
accreditation not only with other safety and quality pro-
grammes, but also with other methods of regulatory
compliance. Although there is no good counterfactual
to accreditation due to widespread implementation,33 we
can estimate the relative effectiveness of accreditation
versus alternative forms of audit. Examples include the
additional requirements that a private ACF would need
to meet to qualify for private health funding, or add-
itional auditing that would be required for public ACFs
in the absence of accreditation.
Sensitivity analysis
A sensitivity analysis is an essential tool to describe the
impact of changes in assumptions and variables on our
SIQNS framework,20 especially given the constraints dis-
cussed. We will review the assumptions in the model and
run the NSB and BCR calculations over a range of
values. For some costs and benefits, including qualitative
outcomes, monetisation will be beyond the scope of this
study and these items will not be included in the NSB or
BCR calculations. Nevertheless, these costs and benefits
can still be included in the final model and used to
compare other programmes with similar NSB or BCR
outcomes, but where the non-monetised items may be a
deciding factor.
ACCREDIT project overview
The ACCREDIT CBA (Acute) study is the 6th of 12 studies
under the ACCREDIT (Accreditation Collaborative for the
Conduct of Research, Evaluation and Designated
Investigations through Teamwork) research collabor-
ation,28 48 49 funded by the Australian Research Council
through its industry Linkage Program.50 The ACCREDIT
collaboration involves researchers in the Centre for
Clinical Governance Research and Centre for Health
Systems and Safety Research in the Australian Institute of
Health Innovation (AIHI) at the University of New South
Wales (UNSW), Australia. The ACCREDIT research team
benefits from a high-profile international advisory group
containing leading researchers in health safety and quality
from the UK, Spain and Sweden. The collaboration
includes two leading health safety and quality bodies
(ACSQHC and the Clinical Excellence Commission
(CEC)) plus three of the major Australian health services
accreditation agencies: ACHS, Australian General Practice
Accreditation Limited (AGPAL) and the Aged Care and
Standards Accreditation Agency (ACSAA).
METHODS AND ANALYSIS
The methods to obtain and analyse data needed to
build the CBA model are discussed below using each of
the five SIQNS activities. For each survey tool, focus
group and expert panel described in the following sec-
tions, the ACCREDIT research team will send an elec-
tronic invitation to potential participants containing the
study information and consent forms approved by the
UNSW Human Research Ethics Committee (HREC).51
Those individuals wishing to participate will be asked to
contact the UNSW research team and will be invited to
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either attend the relevant research activity, at UNSW, or
be interviewed via telephone. The research activities will
last approximately 1 h and will be digitally recorded and
professionally transcribed.
SIQNS activity 1: scope and objectives
The first activity is to review the scope and constraints of
the study design and to establish the study parameters.
This will be completed through three tasks: literature
reviews, analysis of accredited ACFs and stakeholder
identification.
A literature review covering two general issues will be
conducted. First, an investigation of the cost and bene-
fits of accreditation, in health and related fields, and
second, the compliance costs and methodologies used
in non-health industries.
Analysis of accredited ACFs will be conducted using data
from the ACHS national accreditation database, using
accreditation survey data from 2003 to 2011. The purpose
is to assess the characteristics of accredited ACFs: bed size,
ownership and funding structure, geographic location (by
state or territory), type of survey and whether these are
linked to accreditation outcomes. During 2007, ACHS
made changes to the mandatory criteria assessed in the
surveys with the changeover from EQuIP3 to EQuIP4.
Therefore, econometric analysis of the main study variables
will be over the full period (2003–2011), accompanied by
the analysis of individual standards as predictors of accredit-
ation outcomes in the different EQuIP programmes. This
part of the study will provide guidance for reviewing the
structure of the ACFs targeted in the costs study.
To evaluate the stakeholder base, the ACCREDIT
research team will send an electronic invitation to senior
health services researchers at AIHI, UNSW, to partici-
pate in a focus group.52 Those willing to participate will
be asked to contact the ACCREDIT team. The focus
group will take place at UNSW using the general demo-
graphic and content questions from the Stakeholder
Analysis Tool (box 1).
SIQNS activity 2: identify costs and benefits
The aim of this activity is to estimate the incremental costs
and the benefits of accreditation using a variety of
purpose-built tools to both assess and validate our results.
One of the main costs identified in previous research has
been the preparation for external surveys in the accredit-
ation cycle.9 35–38 53 To recruit subjects, the UNSW
research team will send a study invitation to the accredit-
ation partners to forward on to the ACFs they accredit.
The ACFs agreeing to participate will be characterised
according to: facility specialisation (eg, teaching hospital);
location (metropolitan or rural) and size (large, medium
or small). One from each category (n=10) will be ran-
domly selected and approached by the UNSW research
team. Semi-structured interviews will be conducted with
Finance Managers, Quality Managers and General
Managers as directed by the ACF, using the questions set
out in the Incremental Costs Audit Tool (box 2).
Box 1 Stakeholder analysis tool
General demographic questions
▸ What is your age?
▸ What is your gender?
▸ What are your highest qualifications?
▸ What is your research discipline?
▸ How many years have you worked in health services
research?
▸ How many years have you worked as a healthcare
professional?
▸ How many first author peer-reviewed publications do you
have?
▸ How many second or subsequent author publications do you
have?
Content questions
1. Who are the key stakeholders in acute healthcare in Australia?
2. Please classify these as either:
A. Key stakeholders in acute care services who either contribute
to, or influence, the costs and benefits of accreditation or
B. Key stakeholders in acute care services who do not con-
tribute directly to accreditation costs or benefits
3. Please identify the costs and benefits for each stakeholder
identified in 2A
Box 2 Incremental costs audit tool.
1. Demographic details:
A. Bed size of facility.
B. Location (state or territory and whether rural or metropolitan).
C. Funding structure (public or private).
D. Specialisation of the facility (eg, teaching hospital, mental
health, correctional facility or other).
E. Job description of the respondent.
2. Is this your first accreditation cycle?
3. Please provide details, where possible, by year incurred, of
activity-based costing for the following activities in relation to
the accreditation cycle:
A. Notification: implementing recommendations from the
survey.
B. Education: staff meetings, working groups and education
sessions for new staff and to accommodate changes in
standards.
C. Record-keeping: developing and maintaining policies and
documents.
D. Enforcement: staff allocated to assist surveyors and in pre-
survey and postsurvey briefings.
E. Publication and documentation: survey and self-assessment
preparation.
F. Procedural: collecting consumer feedback relating to
accreditation standards.
G. Other: details of staff involved in surveying other facilities.
H. Purchases: survey fees and consultancy fees relating to
accreditation.
4. What do you estimate will be the difference in costs (if any) for
complying with the new National Safety and Quality Health
Service Standards?
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Given the relatively small size of the survey sample, we
will validate the results using an expert panel consisting
of: accreditation surveyors, leading accreditation
researchers, accreditation agencies, health quality con-
sultants and government health quality improvement
agencies. We will also invite staff and surveyors from
ACFs who agreed to participate, but were not selected
for interviews, to take part in the panel. A de-identified
costs summary will be given to participants in advance,
and the panel will be asked to discuss the questions set
out in the Incremental Costs Validation Tool (box 3).
The outcomes of both the incremental costs audit and
validation tools will be assessed against results of the
stakeholder analysis. Total costs will be estimated at the
national level.
To determine the specific benefits of accreditation, we
will use our Indicator Assessment Tool (table 1) to iden-
tify the main topics in the new NSQHS standards and
identify the relevant standard in the ACHS EQuIP5
survey. We will then review a range of process and
outcome indicators including adverse events highlighted
in the NHPA framework,54 as well as the outcome indica-
tors and sentinel events collected by the Australian
Institute of Health and Welfare.55 56
The results of our indicator selection process will be
validated using the established expert panel. A summary
of the potential indicators and scores from the Indicator
Assessment Tool will be given to participants in advance
of the panel. The interviews with the panel will use the
semistructured questions in the Indicator Validation
Tool (box 4).
The results of the panel will be used to formulate a list
of benefit indicators. These will then be mapped to
appropriate databases to look for evidence of improve-
ment over accreditation cycles or following the introduc-
tion of a relevant standard. Indicators with low scores
from the Indicator Assessment Tool, especially for the
proximity and specificity criteria, will be evaluated for
inclusion or rejection.
As this is a high-level description of the protocol, we
have not detailed the exact methods for statistical ana-
lysis as these will depend on the indicators selected. The
main difficulty is in determining a causal effect where
there is no control group given the widespread imple-
mentation of accreditation and we will need to select the
appropriate economic evaluation techniques depending
on the results.
SIQNS activity 3: quantify costs and benefits
Costs will be scaled up nationally according to facility-type
both by an actual dollar amount and as a percentage of
total costs. Identified benefits will be quantified and
monetised using a number of techniques depending on
the type of indicators validated by our expert panel. For
example, clinical outcome indicators can be matched to
the ACSQHC’s Costs of Hospital Acquired Diagnoses
activity-based costing codes.57 58 Process measures are
more difficult to quantify, but techniques for valuing non-
market costs such as revealed and stated preference will
be used to monetise the benefits where possible.21 22 47
SIQNS activity 4: calculate net social benefit
Our interactive CBA model will be populated with the
costs and benefits identified and quantified in SIQNS
activities 2 and 3. Costs will be added to the model and
Box 3 Incremental costs validation tool
1. Do you think the results from the audit tool are representative
of the current accreditation process?
2. If these costs are not representative, what is your estimate of
the costs?
3. Are there other incremental costs that have not been included?
4. What would be your estimate of costs identified in question 3?
Box 4 Indicator validation tool.
1. Do you think the indicators selected using the Indicator
Assessment Tool are representative of the benefits of
accreditation?
2. If these are not representative, what indicators would you add
and why?
3. For the indicators you have identified, would you recommend
attaching a weighting to the monetised values and if so, what
weighting would you recommend?








Identify the relevant NSQHS standard
ACHS EQuIP5 Whether the intervention is a
mandatory criterion in EQuIP5
Indicator Description of indicator
Indicator type Whether the indicator is process
based or outcome based
Research What is the evidence base that
compliance with the standard affects
the indicator?
Accuracy How accurate is the indicator in terms
of measuring compliance with the
accreditation standard?
Proximity How close is the link between the




What is the risk of avoiding adverse
effects?
Specificity Is it possible to isolate the effects of
accreditation on the indicator from
other safety and quality programmes?
Associate
programmes
Related programmes initiated by state
or federal governments, or healthcare
agencies
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allocated by the year in which they were incurred during
the accreditation cycle. The benefits will be allocated
depending on the type of indicator used. For example,
for clinical indicators such as hospital-acquired infection
rates, the cost savings from a reduction in infection rates
per year nationally can be monetised and modelled.
Where the timing is not clear, we will assign equal weights
over the expected time horizon and discount accordingly.
Australian Government approved discount rates will be
applied to the model in order to discount the cost and
benefit cash flows back to a baseline year.19 59 Both the
NSB and BCR (equations 1 and 2) will be calculated for
the costs and benefits that have been monetised.
Non-monetised costs and benefits will be included for











Equations 1 and 2: Bt is the sum of benefits in year t; Ct
the sum of costs in year t; n the lifetime of the accredit-
ation cycle or expected time horizon, in years; and r the
discount rate used.
SIQNS activity 5: sensitivity analysis
In order to determine the sensitivity of inputs into the
model, NSB and BCR will be recalculated for a range of
values (±1, 5 and 10% of the total values) for each indi-
vidual cost and benefit that is more than 10% of the
total. In addition, the model will be run with discount
rates at ±2 and 5 percentage points from the base dis-
count rates used in order to test the duration sensitivity
of the model.
ETHICS AND DISSEMINATION
The UNSW HREC has approved the ACCREDIT-CBA
(Acute) study proposal (approval number HREC10 274).
The study will be conducted in accordance with the
UNSW Research Code of Conduct and the Australian
National Health and Medical Research Council
(NHMRC) guidelines.60 61 As such, all project data will be
de-identified prior to publication and stored securely for a
minimum of 7 years. Contact details of the research team
will be given to participants in the study so that any com-
plaints or concerns can be addressed. The results of the
study will be submitted for publication in selected journals
and presented at national and international conferences
and seminars. The findings will also form part of a doc-
toral thesis.
CONCLUSION
Although accreditation of acute health services has been
widely adopted in Australia, little is currently known
about the costs and benefits of the process and whether
accreditation is a cost-effective tool in improving patient
safety and quality of care. This study aims to create a
framework to answer these questions and to make the
costs and benefits of accreditation explicit. This will, in
turn, inform debate on the important issue of how best
to monitor and improve patient safety and quality of
care in acute health services.
Author affiliations
1Centre for Clinical Governance Research, Australian Institute of Health
Innovation, University of New South Wales, Sydney, New South Wales,
Australia
2School of Public Health and Community Medicine, University of New South
Wales, Sydney, New South Wales, Australia
3Centre for Health Systems and Safety Research, Australian Institute of Health
Innovation, University of New South Wales, Sydney, New South Wales,
Australia
Acknowledgements We acknowledge the staff of the industry partners
(ACHS, AGPAL, ACSAA) and the quality improvement agencies (ACSQHC and
CEC) who provided support for the project.
Contributors VM was responsible for developing the SIQNS evaluation
framework, in consultation with JB and KF and initial draft of the manuscript.
JB and JIW are the chief investigators of the ACCREDIT project and helped
conceptualise the overall research study design. DG contributed to the
framework and designed the format of the research tools, substantially
revising the draft manuscript. RH and MM also contributed to the
development of the framework and research tools. All authors provided critical
feedback in developing the manuscript and approved the final version.
Funding This research is supported under the Australian Research Council’s
Linkage Projects scheme (project LP100200586) and NHMRC Program grant
number 568 612. Although the ARC and NHMRC have contributed to the
funding of the research, the final responsibility for all research activities,
including the decision to publish the results of the studies, resides with
UNSW.
Competing interests None.
Ethics approval University of New South Wales, Human Research Ethics
Committee (approval number HREC 10274).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data available on request from the corresponding
author.
REFERENCES
1. Shaw CD. Evaluating accreditation. Int J Qual Health Care
2003;15:455–6.
2. Braithwaite J, Greenfield D, Westbrook J, et al. Health service
accreditation as a predictor of clinical and organisational
performance: a blinded, random, stratified study. Qual Saf Health
Care 2010;19:14–21.
3. Greenfield D, Pawsey M, Braithwaite J. The role and impact of
accreditation on the healthcare revolution (O papel e o impacto da
acreditação na revolução da atenção à saúde). Acreditação
2012;1:64–7.
4. Greenfield D, Braithwaite J. Health sector accreditation research: a
systematic review. Int J Qual Health Care 2008;20:172–83.
5. Hinchcliff R, Greenfield D, Moldovan M, et al. Narrative synthesis of
health service accreditation literature. BMJ Qual Saf
2012;21:979–91.
6. ISQuA. Dublin: The International Society for Quality in Health Care
Ltd—Articles of Association, 2011.
7. The Joint Commission. Benefits of Joint Commission Accreditation,
http://www.jointcommission.org/accreditation/accreditation_main.
aspx (accessed Aug 2012).
8. Greenfield D, Pawsey M, Braithwaite J. Accreditation: a global
regulatory mechanism to promote quality and safety. In: Sollecito W,
Mumford V, Greenfield D, Hinchcliff R, et al. BMJ Open 2013;3:e002381. doi:10.1136/bmjopen-2012-002381 7
Accredit-CBA (Acute)
group.bmj.com on September 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Johnson J. Continuous quality improvement in health care: theory,
implementations and applications. 4th edn. New York: Jones and
Bartlett, 2013: 513–36.
9. Fairbrother G, Gleeson M. EQuIP accreditation: feedback from a
Sydney teaching hospital. Aust Health Rev 2000;23:153–62.
10. Australian Council on Healthcare Standards. The ACHS National
Report on Health Services Accreditation Performance 2009–2010.
Sydney, 2011.
11. Commonwealth Government of Australia. A national health and
hospitals network for Australia’s future. Canberra: Department of
Health and Ageing, 2010.
12. OECD. Health Data. Institution, 2012. http://www.oecd.org/els/
healthpoliciesanddata/oecdhealthdata2012.htm (accessed Nov
2012).
13. Kohn L, Corrigan J, Donaldson M. To err is human: building a safer
health system. Committee on Quality of Health Care in America
—Washington: Institute of Medicine, 2000.
14. Runciman WB, Webb RK, Helps SC, et al. A comparison of
iatrogenic injury studies in Australia and the USA II: reviewer
behaviour and quality of care. Int J Qual Health Care
2000;12:379–88.
15. De Vries EN, Ramrattan MA, Smorenburg SM, et al. The incidence
and nature of in-hospital adverse events: a systematic review. Qual
Saf Health Care 2008;17:216–23.
16. Hauck K, Zhao X, Jackson T. Adverse event rates as measures of
hospital performance. Health Policy 2012;104:146–54.
17. Squires D. Using comparative effectiveness research to inform
policymaking. New York: The Commonwealth Fund, 2012.
18. National Health and Hospitals Reform Commission. Beyond the
blame game: accountability and performance benchmarks for the
next Australian Health Care Agreements. Canberra: NHHRC, 2008.
19. Australian Government. Best practice regulation guidance note:
decision rules in regulatory cost-benefit analysis. Canberra: OBPR,
2009
20. Commonwealth of Australia. Handbook of cost-benefit analysis.
Canberra: Department of Finance and Administration, 2006.
21. HM Treasury. The Green book: appraisal and evaluation in central
government. London: TSO, 2003 (updated 2011).
22. Drummond MF, Sculpher M, Torrance G, et al. Methods for the
economic evaluation of health care programmes. 3rd edn. Oxford:
Oxford Medical Publications, 2005.
23. Gray A, Clarke P, Wolstenhome J, et al. Applied methods of
cost-effectiveness analysis in health care: Oxford: Oxford University
Press, 2011.
24. National Institute for Health and Clinical Excellence. Updated guide
to the methods of technology appraisal. London: NICE, 2008.
25. Pharmaceutical Benefits Advisory Committee. Guidelines for the
pharmaceutical industry on preparation of submissions to the
Pharmaceutical Benefits Advisory Committee: including major
submissions involving economic analyses. Canberra: Australian
Government Department for Health and Ageing, 1995.
26. McIntosh E, Clarke B, Frew E, et al. Applied methods of cost-benefit
analysis in health care. Oxford: Oxford University Press, 2010.
27. Shiell A, Hawe P, Gold L. Complex interventions or complex
systems? Implications for health economic evaluation. BMJ
2008;336:1281–3.
28. Braithwaite J, Westbrook J, Johnston B, et al. Strengthening
organizational performance through accreditation research—a
framework for twelve interrelated studies: the ACCREDIT project
study protocol. BMC Res Notes 2011;4:390.
29. Øvretveit J. Quality evaluation and indicator comparison in health
care. Int J Health Plann Manag 2001;16:229–41.
30. Flodgren G, Pomey M, Taber S, et al. Effectiveness of external
inspection of compliance with standards in improving healthcare
organisation behaviour, healthcare professional behaviour or patient
outcomes. Cochrane Database Syst Rev 2011;2:1–43.
31. Appleyard G, John Ramsay and Associates Pty Ltd. Cost analysis of
safety and quality accreditation in the Australian health system.
Sydney: Australian Commission for Safety and Quality in Health
Care, 2008
32. Imbens GW, Wooldridge JM. Recent developments in the
econometrics of program evaluation. J Econ Lit 2009;47:5–86.
33. Australian Institute of Health and Welfare. Australia’s hospitals
2009–10: at a glance. Health services series no.39. Cat. no. HSE
106. Canberra: AIHW, 2011.
34. Productivity Commission. General practice administrative and
compliance costs—research report. Canberra: Productivity
Commission, 2003.
35. Foster BJ, Gipe B. A detailed analysis of the costs of a JCAHO
survey. Cost Qual Q J: 1997;3:19–24.
36. Mihalik G, Scherer M, Schreter R. The high price of quality: a
cost analysis of NCQA accreditation. J Health Care Finance
2003;29:38.
37. Rockwell DA, Pelletier LR, Donnelly W. The cost of accreditation:
one hospital’s experience. Hosp Community Psychiatry
1993;44:151–5.
38. Zarkin GA, Dunlap LJ, Homsi G. The costs of pursuing accreditation
for methadone treatment sites: results from a national study. Eval
Rev 2006;30:119–38.
39. Australian Government. Business cost calculator. Department of
Finance and Deregulation. Canberra: OBPR, 2008.
40. Accreditation Canada. Canadian Health Accreditation Report
—required organizational practices: emerging risks, focused
improvements. Ottowa: Accreditation Canada, 2012.
41. Australian Commission on Safety and Quality in Health Care.
National safety and quality health service standards and their use in
a model national accreditation scheme: decision regulatory impact
statement. Sydney: ACSQHC, 2010.
42. Chassin MR, Loeb JM, Schmaltz SP, et al. Accountability measures
—using measurement to promote quality improvement. New Engl J
Med 2010;363:683–8.
43. Mant J. Process versus outcome indicators in the assessment of
quality of health care. Int J Qual Health Care 2001;13:475–80.
44. Brook R, McGlynn E, Shekelle P. Defining and measuring quality of
care: a perspective from US researchers. Int J Qual Health Care
2000;12:281–95.
45. Øvretveit J, Gustafson D. Evaluation of quality improvement
programmes. Qual Saf Health Care 2002;11:270–5.
46. Doyle G, Grampp C. The cost of implementing accreditation: what
are the benefits? final report of the retrospective study. Health
Information and Quality Authority: Dublin: Irish Health Services
Accreditation Board, 2008.
47. Fujiwara D, Campbell R. Valuation techniques for social cost-benefit
analysis: stated preference, revealed preference and subjective
well-being approaches. A discussion of the current issues. London:
Department for Work and Pensions, HM Treasury, 2011.
48. Hinchcliff R, Greenfield D, Moldovan M, et al. Evaluation of
current Australian health service accreditation processes
(ACCREDIT-CAP): protocol for a mixed-method research project.
BMJ Open 2012;2:e001726.
49. Greenfield D, Hinchcliff R, Moldovan M, et al. A multimethod
research investigation of consumer involvement in Australian Health
Service accreditation programmes: the ACCREDIT-SCI study
protocol. BMJ Open 2012;2:e002024.
50. Australian Research Council. Linkage projects. Canberra:
Commonwealth of Australia, 2012.
51. University of New South Wales. Operations manual for the Human
Research Ethics Committee (HREC), Sydney: UNSW, 2010.
52. Bender DE, Ewbank D. The focus group as a tool for health
research: issues in design and analysis. Health Transit Rev
1994;4:63–80.
53. Bukonda N, Tavrow P, Abdallah H, et al. Implementing a national
hospital accreditation program: the Zambian experience. Int J Qual
Health Care 2002;14(Suppl 1):7–16.
54. National Health Performance Authority. National health reform:
performance and accountability framework. Canberra: NHPA,
2012.
55. Australian Institute for Health and Welfare. A set of performance
indicators across the health and aged care system. Canberra: AIHW,
2008.
56. Australian Institute for Health and Welfare & Australian Commission
on Safety and Quality in Health Care. Sentinel events in Australian
public hospitals 2004–2005. Canberra: AIHW, 2007.
57. Jackson TJ, Michel JL, Roberts RF, et al. A classification of
hospital-acquired diagnoses for use with routine hospital data. Med J
Aust 2009;191:544–8.
58. Jackson T, Nghiem HS, Rowell D, et al. Marginal costs of
hospital-acquired conditions: information for priority-setting for
patient safety programmes and research. J Health Serv Res Policy
2011;16:141–6.
59. National Health and Medical Research Council. How to compare the
costs and benefits: evaluation of the economic evidence. Canberra:
Commonwealth of Australia, 2001
60. National Health and Medical Research Council of Australia. National
statement on ethical conduct in human research. Canberra:
NHMRC, 2007 (updated 2009).
61. University of New South Wales A research code of conduct: Version
1.0 effective 27 April 2009.
62. The SROI Network. A guide to social return on investment. London:
UK Cabinet Office, 2012.
8 Mumford V, Greenfield D, Hinchcliff R, et al. BMJ Open 2013;3:e002381. doi:10.1136/bmjopen-2012-002381
Accredit-CBA (Acute)
group.bmj.com on September 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
project
study protocol for a mixed-method research
accreditation (ACCREDIT-CBA (Acute)): 
Economic evaluation of Australian acute care
Kevin Forde, Johanna I Westbrook and Jeffrey Braithwaite
Virginia Mumford, David Greenfield, Reece Hinchcliff, Max Moldovan,
doi: 10.1136/bmjopen-2012-002381
2013 3: BMJ Open 
 http://bmjopen.bmj.com/content/3/2/e002381




This article cites 28 articles, 6 of which you can access for free at: 
Open Access
.http://creativecommons.org/licenses/by-nc/2.0/legalcode
 and http://creativecommons.org/licenses/by-nc/2.0/with the license. See: 
properly cited, the use is non commercial and is otherwise in compliance 
distribution, and reproduction in any medium, provided the original work is
Commons Attribution Non-commercial License, which permits use, 
This is an open-access article distributed under the terms of the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on September 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
